OptiLight in the Dry Eye Practice with Arthur Benjamin, MD

In this episode, Arthur Benjamin, MD, discusses dry eye treatment and trends, the challenges dry eye patients and the eye care professionals treating them and more.

• Intro :37
• Welcome to another episode of Eye Care insider :51
• About Arthur Benjamin, MD 1:02
• I wonder if you could talk about your training and what you currently do now? 1:39
• Could you talk about what you’ve seen throughout the years and what you’ve seen in the trends in dry eye and how it has expanded in the population? 2:56
• What is your current algorithm for someone with dry eye? How do you manage that? 5:01
• Once you do determine they have moderate dry eye where do you start with the patient or the treatment paradigm? 7:00
• With the OptiLight treatment option … what do you tell patients? What should they be expecting? 9:54
• I recently saw that there’s been a campaign from OptiLight involving Mandy Moore. Could you talk about that campaign and discuss it a little bit further? 12:54
• What do you think is the most important topic or issue or challenge that are facing dry eye patients today or eye care professionals treating patients with dry eye? 16:07
• What a fascinating discussion 17:43
• Any last words? 17:55
• Outro 18:09

Arthur Benjamin, MD, is a clinical assistant professor at the Jules Stein/Doheny Eye Institute at UCLA’s Geffen School of Medicine and is in private practice at Benjamin Eye Institute.  

We’d love to hear from you! Send your comments/questions to Dr. Mali at [e-mail]. Follow us on Twitter @Healio_OSN. Dr. Benjamin can be contacted by going to BenjaminEye.com.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Benjamin reports no relevant financial disclosures.